Summary

The global Uterine Fibroid Treatment market is projected to grow from US$ 3267 million in 2025 to US$ 4688 million by 2032, at a CAGR of 5.4% (2026-2032), driven by critical product segments and diverse end‑use applications.

Uterine fibroid treatment refers to a range of medical interventions targeting benign smooth muscle tumors of the uterus, including pharmacological therapies, interventional procedures, minimally invasive surgeries, and traditional open surgeries. These treatments aim to alleviate symptoms such as heavy menstrual bleeding, pelvic pain, and infertility, while preserving uterine function whenever possible. With the advancement of minimally invasive techniques, imaging-guided technologies, and novel therapeutics, uterine fibroid treatments are evolving toward personalized, precise, and low-risk approaches to meet diverse patient needs and improve quality of life.

Key Findings
Uterus-preserving minimally invasive treatment is reshaping clinical practice
Radiofrequency ablation is expanding the treatment technology portfolio
Embolization maintains an established role in interventional treatment
Hysteroscopic systems address intracavitary and submucosal fibroid removal
Disposable components create recurring revenue beyond capital equipment
Image-guided treatment is improving procedural precision and patient selection

Market Trends
The Uterine Fibroid Treatment market is moving from conventional surgery-centered treatment toward a broader portfolio of uterus-preserving, minimally invasive, and image-guided procedures. A major technology direction is the closer integration of visualization and therapy: transcervical radiofrequency platforms combine intrauterine ultrasound with controlled energy delivery, while magnetic resonance-guided focused ultrasound enables non-incisional thermal treatment and hysteroscopic systems combine direct visualization, tissue resection, evacuation, and fluid management. Hologic’s Sonata platform, for example, integrates real-time intrauterine ultrasound with radiofrequency ablation, while Medtronic’s TruClear platform combines hysteroscopic visualization with mechanical tissue removal and suction. These technology architectures illustrate a broader shift toward precise lesion targeting, reduced access trauma, simplified procedural workflows, and greater suitability for outpatient or shorter-stay treatment settings.

Another structural trend is the increasing importance of procedure-specific consumables and integrated treatment ecosystems. Capital systems are increasingly paired with single-use ablation handpieces, tissue shavers, electrodes, embolization microspheres, catheters, and other procedural accessories, making treatment volume an important driver of recurring demand. In uterine fibroid embolization, manufacturers continue to refine microsphere calibration, material composition, catheter compatibility, and delivery characteristics; Terumo’s HYDROPEARL portfolio, for example, uses calibrated polyethylene glycol microspheres and is indicated for symptomatic uterine fibroid embolization. This trend is gradually shifting competition from standalone devices toward complete procedure platforms combining equipment, consumables, workflow support, and physician training.

Market Dynamics
Drivers
Demand for Uterine Fibroid Treatment devices and consumables is supported by the high clinical burden of symptomatic fibroids, greater emphasis on uterus preservation, and continuing migration toward less invasive intervention. Women seeking alternatives to hysterectomy and conventional myomectomy are expanding the addressable population for ablation, embolization, and hysteroscopic procedures. At the same time, advances in imaging, energy delivery, embolic materials, hysteroscopic visualization, and fluid management are allowing physicians to treat a wider range of fibroid locations through differentiated procedural pathways. Hospital and ambulatory providers also have incentives to adopt technologies that can reduce incision requirements, shorten recovery pathways, and support same-day or outpatient care where clinically appropriate. Official product documentation from major manufacturers demonstrates continued development of transcervical ablation, mechanical hysteroscopic removal, embolization, and image-guided non-invasive treatment technologies.

Restraints
Market expansion remains constrained by treatment-selection complexity and the fact that no single technology is suitable for all fibroid types, sizes, locations, fertility objectives, and patient profiles. Adoption of advanced platforms may require substantial capital equipment, imaging infrastructure, dedicated physician training, and procedure-specific workflow changes. Magnetic resonance-guided approaches have comparatively high infrastructure requirements, while embolization depends on interventional radiology capabilities and careful vascular technique. Hysteroscopic technologies are primarily relevant to lesions accessible from the uterine cavity, whereas ablation outcomes and procedural suitability depend on fibroid anatomy. The resulting need for individualized treatment planning limits standardized adoption and can slow technology penetration in facilities with lower procedure volumes or limited multidisciplinary capability.

Opportunities
The strongest opportunities lie in expanding uterus-preserving treatment to patient groups that historically faced a narrower choice between medication and surgery. Further miniaturization of instruments, improved energy control, enhanced imaging guidance, more intuitive treatment-planning software, and procedure-specific disposable designs can broaden physician adoption and improve workflow efficiency. Outpatient gynecology and ambulatory surgical settings also provide an opportunity for systems designed around compact equipment, simplified setup, shorter procedure cycles, and predictable consumable use. In embolization, advances in microsphere calibration and delivery systems can support more standardized procedural performance, while image-guided ablation creates opportunities to address selected fibroids without conventional excision. Emerging markets represent an additional opportunity as gynecologic intervention capabilities, interventional radiology infrastructure, and access to advanced imaging continue to develop.

Challenges
A central industry challenge is demonstrating durable clinical value across heterogeneous fibroid populations while maintaining acceptable procedure economics. Manufacturers must establish physician familiarity, clinical evidence, reimbursement pathways, training programs, and procedural support simultaneously, making commercialization more complex than for conventional standalone instruments. Competition also occurs across fundamentally different treatment modalities rather than only between similar products: radiofrequency ablation, focused ultrasound, hysteroscopic removal, embolization, and conventional surgery can all compete for overlapping patient groups. Long-term market development therefore depends on clearly defining the appropriate patient population for each technology, generating evidence on symptom control and retreatment, and integrating new systems into existing gynecology and interventional radiology pathways.

Industry Chain Analysis
The upstream Uterine Fibroid Treatment industry consists of medical-grade polymers, metallic alloys, radiofrequency energy components, ultrasound transducers, magnetic resonance-compatible materials, optical and imaging components, electronic control modules, surgical blades, electrodes, catheter materials, microsphere polymers, and sterile packaging. Regulatory-grade manufacturing, precision machining, biocompatibility, sterilization, software development, and quality systems are particularly important because many treatment platforms combine reusable equipment with patient-contacting disposable components. In embolization, material properties and particle-size consistency directly influence product design, while ablation platforms depend on accurate energy control and imaging integration. Hysteroscopic systems add further requirements for visualization, fluid management, tissue cutting, and evacuation.

The midstream combines system development, device manufacturing, sterile consumable production, regulatory registration, clinical training, and distribution. Downstream demand is generated mainly by hospitals, gynecology centers, interventional radiology departments, ambulatory surgery facilities, and specialized women’s health centers. Value creation differs by modality: capital-intensive systems derive value from installed equipment and utilization, whereas disposable handpieces, tissue shavers, embolic agents, and related procedure kits generate recurring revenue as procedure volumes increase. As a result, manufacturers with integrated capital equipment, consumables, physician training, and procedural support can build stronger customer relationships than suppliers competing only on individual components.

Segment Insights
From a technology perspective, the market is increasingly diversified across radiofrequency ablation, focused ultrasound ablation, hysteroscopic tissue removal and resection, and uterine fibroid embolization. Radiofrequency ablation represents an important technology opportunity because it can be delivered through transcervical or laparoscopic access and combines controlled thermal treatment with uterus-preserving positioning. Transcervical platforms are particularly differentiated by integrating intrauterine imaging and ablation within the same procedure. Focused ultrasound occupies a more infrastructure-intensive but fully non-incisional segment, using image guidance to thermally treat selected fibroids without transvascular or transcervical instrumentation. Profound Medical continues to identify uterine fibroids among the gynecologic applications of its magnetic resonance-guided Sonalleve platform.

Hysteroscopic tissue removal and resection remain important for intracavitary and submucosal disease because they provide direct visualization and immediate physical removal of accessible tissue. Mechanical systems emphasize tissue cutting and simultaneous evacuation, while bipolar systems combine resection, coagulation, visualization, and fluid management. Minerva Surgical’s Symphion system, for example, is intended for resection and coagulation of intrauterine tissue including myomas. Embolization represents a distinct interventional segment in which recurring consumables account for a significant part of the product value proposition, with competition focused on embolic materials, particle calibration, microcatheter delivery, and procedure support rather than on a single capital platform.

Downstream Market Opportunities
Downstream opportunities are increasingly linked to matching treatment modality with fibroid anatomy and care setting. Gynecology departments and ambulatory surgical centers create demand for transcervical ablation and hysteroscopic treatment technologies that can support minimally invasive workflows, while interventional radiology departments form the core customer base for uterine fibroid embolization products. Advanced imaging centers and selected hospitals support magnetic resonance-guided focused ultrasound procedures. The commercial opportunity extends beyond equipment sales because growing utilization of installed platforms increases demand for disposable handpieces, shavers, electrodes, embolization particles, catheters, and supporting procedural products. Systems that reduce setup complexity, integrate imaging and treatment, and support same-day treatment pathways are therefore positioned to benefit from continued decentralization of selected fibroid procedures.

Regional Insights
North America represents a key commercial market for advanced Uterine Fibroid Treatment technologies, supported by established gynecologic surgery, interventional radiology, ambulatory care, and reimbursement infrastructure. The region has commercial availability of multiple treatment approaches spanning transcervical and laparoscopic radiofrequency ablation, hysteroscopic tissue removal, and uterine fibroid embolization. Manufacturer investment in physician education and procedure-specific resources further supports technology adoption. Europe similarly offers a diversified treatment environment, with strong participation in hysteroscopic, embolization, and image-guided treatment, although reimbursement and hospital procurement structures vary considerably by country.

Asia-Pacific offers longer-term expansion potential as access to minimally invasive gynecology, advanced imaging, and interventional radiology increases. The regional opportunity is heterogeneous: developed markets have established hospital infrastructure and greater capability to adopt sophisticated capital systems, while emerging markets are more sensitive to acquisition cost, training requirements, and utilization economics. China is also relevant to the development of magnetic resonance-guided treatment infrastructure; Profound Medical states that Sonalleve has regulatory clearance or approval in China among its international markets. Regional growth will therefore depend not only on disease prevalence but also on procedure reimbursement, physician training, imaging availability, hospital capital budgets, and the development of multidisciplinary fibroid treatment pathways.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Uterine Fibroid Treatment market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by End Use, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
Boston Scientific
CooperSurgical
Karl Storz
Merit Medical
Olympus
Richard Wolf
Chongqing Haifu
Haiying Medical
Puluo Medical
Shanghai Aishen Technology
Hologic
Medtronic
Terumo
INSIGHTEC
Profound Medical

Segment by Type
Operation Treatment
Ablation Technique
Embolization Technique

Segment by Treatment Modality
Minimally Invasive Procedures
Surgical Therapy
Other

Segment by Technological Approach
Image-Guided Therapy
Robotic-Assisted Surgery
Other

Segment by End Use
Transcervical Fibroid Ablation
Laparoscopic Fibroid Ablation
Hysteroscopic Myomectomy
Uterine Fibroid Embolization (UFE/UAE)
Other

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Uterine Fibroid Treatment study scope, segments the market by Type and by End Use, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by End Use, identifies emerging use cases, and profiles leading customers by region and by End Use
Chapter 6: North America: breaks down market size by End Use and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by End Use and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by End Use, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by End Use, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by End Use, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by End Use, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Uterine Fibroid Treatment: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Uterine Fibroid Treatment Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Operation Treatment
1.2.3 Ablation Technique
1.2.4 Embolization Technique
1.3 Market Segmentation by Treatment Modality
1.3.1 Global Uterine Fibroid Treatment Market Size by Treatment Modality, 2021 vs 2025 vs 2032
1.3.2 Minimally Invasive Procedures
1.3.3 Surgical Therapy
1.3.4 Other
1.4 Market Segmentation by Technological Approach
1.4.1 Global Uterine Fibroid Treatment Market Size by Technological Approach, 2021 vs 2025 vs 2032
1.4.2 Image-Guided Therapy
1.4.3 Robotic-Assisted Surgery
1.4.4 Other
1.5 Market Segmentation by End Use
1.5.1 Global Uterine Fibroid Treatment Market Size by End Use, 2021 vs 2025 vs 2032
1.5.2 Transcervical Fibroid Ablation
1.5.3 Laparoscopic Fibroid Ablation
1.5.4 Hysteroscopic Myomectomy
1.5.5 Uterine Fibroid Embolization (UFE/UAE)
1.5.6 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Uterine Fibroid Treatment Revenue Estimates and Forecasts (2021-2032)
2.2 Global Uterine Fibroid Treatment Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Uterine Fibroid Treatment Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Uterine Fibroid Treatment Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Operation Treatment: Market Share by Key Players
3.3.2 Ablation Technique: Market Share by Key Players
3.3.3 Embolization Technique: Market Share by Key Players
3.4 Global Uterine Fibroid Treatment Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Uterine Fibroid Treatment Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Uterine Fibroid Treatment Market by Treatment Modality
4.2.1 Global Revenue by Treatment Modality (2021-2032)
4.2.2 Global Revenue-Based Market Share by Treatment Modality (2021-2032)
4.3 Global Uterine Fibroid Treatment Market by Technological Approach
4.3.1 Global Revenue by Technological Approach (2021-2032)
4.3.2 Global Revenue-Based Market Share by Technological Approach (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Uterine Fibroid Treatment Revenue by End Use
5.1.1 Global Historical and Forecasted Revenue by End Use (2021-2032)
5.1.2 Revenue-Based Market Share by End Use (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by End Use

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Uterine Fibroid Treatment Market Size by End Use (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Uterine Fibroid Treatment Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Uterine Fibroid Treatment Market Size by End Use (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Uterine Fibroid Treatment Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Uterine Fibroid Treatment Market Size by End Use (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Uterine Fibroid Treatment Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Uterine Fibroid Treatment Market Size by End Use (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Uterine Fibroid Treatment Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Uterine Fibroid Treatment Market Size by End Use (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Uterine Fibroid Treatment Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Boston Scientific
11.1.1 Boston Scientific Corporation Information
11.1.2 Boston Scientific Business Overview
11.1.3 Boston Scientific Uterine Fibroid Treatment Product Features and Attributes
11.1.4 Boston Scientific Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.1.5 Boston Scientific Uterine Fibroid Treatment Revenue by Product in 2025
11.1.6 Boston Scientific Uterine Fibroid Treatment Revenue by End Use in 2025
11.1.7 Boston Scientific Uterine Fibroid Treatment Revenue by Geographic Area in 2025
11.1.8 Boston Scientific Uterine Fibroid Treatment SWOT Analysis
11.1.9 Boston Scientific Recent Developments
11.2 CooperSurgical
11.2.1 CooperSurgical Corporation Information
11.2.2 CooperSurgical Business Overview
11.2.3 CooperSurgical Uterine Fibroid Treatment Product Features and Attributes
11.2.4 CooperSurgical Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.2.5 CooperSurgical Uterine Fibroid Treatment Revenue by Product in 2025
11.2.6 CooperSurgical Uterine Fibroid Treatment Revenue by End Use in 2025
11.2.7 CooperSurgical Uterine Fibroid Treatment Revenue by Geographic Area in 2025
11.2.8 CooperSurgical Uterine Fibroid Treatment SWOT Analysis
11.2.9 CooperSurgical Recent Developments
11.3 Karl Storz
11.3.1 Karl Storz Corporation Information
11.3.2 Karl Storz Business Overview
11.3.3 Karl Storz Uterine Fibroid Treatment Product Features and Attributes
11.3.4 Karl Storz Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.3.5 Karl Storz Uterine Fibroid Treatment Revenue by Product in 2025
11.3.6 Karl Storz Uterine Fibroid Treatment Revenue by End Use in 2025
11.3.7 Karl Storz Uterine Fibroid Treatment Revenue by Geographic Area in 2025
11.3.8 Karl Storz Uterine Fibroid Treatment SWOT Analysis
11.3.9 Karl Storz Recent Developments
11.4 Merit Medical
11.4.1 Merit Medical Corporation Information
11.4.2 Merit Medical Business Overview
11.4.3 Merit Medical Uterine Fibroid Treatment Product Features and Attributes
11.4.4 Merit Medical Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.4.5 Merit Medical Uterine Fibroid Treatment Revenue by Product in 2025
11.4.6 Merit Medical Uterine Fibroid Treatment Revenue by End Use in 2025
11.4.7 Merit Medical Uterine Fibroid Treatment Revenue by Geographic Area in 2025
11.4.8 Merit Medical Uterine Fibroid Treatment SWOT Analysis
11.4.9 Merit Medical Recent Developments
11.5 Olympus
11.5.1 Olympus Corporation Information
11.5.2 Olympus Business Overview
11.5.3 Olympus Uterine Fibroid Treatment Product Features and Attributes
11.5.4 Olympus Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.5.5 Olympus Uterine Fibroid Treatment Revenue by Product in 2025
11.5.6 Olympus Uterine Fibroid Treatment Revenue by End Use in 2025
11.5.7 Olympus Uterine Fibroid Treatment Revenue by Geographic Area in 2025
11.5.8 Olympus Uterine Fibroid Treatment SWOT Analysis
11.5.9 Olympus Recent Developments
11.6 Richard Wolf
11.6.1 Richard Wolf Corporation Information
11.6.2 Richard Wolf Business Overview
11.6.3 Richard Wolf Uterine Fibroid Treatment Product Features and Attributes
11.6.4 Richard Wolf Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.6.5 Richard Wolf Recent Developments
11.7 Chongqing Haifu
11.7.1 Chongqing Haifu Corporation Information
11.7.2 Chongqing Haifu Business Overview
11.7.3 Chongqing Haifu Uterine Fibroid Treatment Product Features and Attributes
11.7.4 Chongqing Haifu Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.7.5 Chongqing Haifu Recent Developments
11.8 Haiying Medical
11.8.1 Haiying Medical Corporation Information
11.8.2 Haiying Medical Business Overview
11.8.3 Haiying Medical Uterine Fibroid Treatment Product Features and Attributes
11.8.4 Haiying Medical Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.8.5 Haiying Medical Recent Developments
11.9 Puluo Medical
11.9.1 Puluo Medical Corporation Information
11.9.2 Puluo Medical Business Overview
11.9.3 Puluo Medical Uterine Fibroid Treatment Product Features and Attributes
11.9.4 Puluo Medical Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.9.5 Puluo Medical Recent Developments
11.10 Shanghai Aishen Technology
11.10.1 Shanghai Aishen Technology Corporation Information
11.10.2 Shanghai Aishen Technology Business Overview
11.10.3 Shanghai Aishen Technology Uterine Fibroid Treatment Product Features and Attributes
11.10.4 Shanghai Aishen Technology Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Hologic
11.11.1 Hologic Corporation Information
11.11.2 Hologic Business Overview
11.11.3 Hologic Uterine Fibroid Treatment Product Features and Attributes
11.11.4 Hologic Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.11.5 Hologic Recent Developments
11.12 Medtronic
11.12.1 Medtronic Corporation Information
11.12.2 Medtronic Business Overview
11.12.3 Medtronic Uterine Fibroid Treatment Product Features and Attributes
11.12.4 Medtronic Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.12.5 Medtronic Recent Developments
11.13 Terumo
11.13.1 Terumo Corporation Information
11.13.2 Terumo Business Overview
11.13.3 Terumo Uterine Fibroid Treatment Product Features and Attributes
11.13.4 Terumo Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.13.5 Terumo Recent Developments
11.14 INSIGHTEC
11.14.1 INSIGHTEC Corporation Information
11.14.2 INSIGHTEC Business Overview
11.14.3 INSIGHTEC Uterine Fibroid Treatment Product Features and Attributes
11.14.4 INSIGHTEC Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.14.5 INSIGHTEC Recent Developments
11.15 Profound Medical
11.15.1 Profound Medical Corporation Information
11.15.2 Profound Medical Business Overview
11.15.3 Profound Medical Uterine Fibroid Treatment Product Features and Attributes
11.15.4 Profound Medical Uterine Fibroid Treatment Revenue and Gross Margin (2021-2026)
11.15.5 Profound Medical Recent Developments

12 Uterine Fibroid Treatment Value Chain and Ecosystem Analysis
12.1 Uterine Fibroid Treatment Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Uterine Fibroid Treatment Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Uterine Fibroid Treatment Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Uterine Fibroid Treatment Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Uterine Fibroid Treatment Market Size Growth Rate by Treatment Modality, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Uterine Fibroid Treatment Market Size Growth Rate by Technological Approach, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Uterine Fibroid Treatment Market Size Growth Rate by End Use, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Uterine Fibroid Treatment Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Uterine Fibroid Treatment Revenue by Region (US$ Million), 2021-2026
Table 7. Global Uterine Fibroid Treatment Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Uterine Fibroid Treatment Revenue by Players (US$ Million), 2021-2026
Table 10. Global Uterine Fibroid Treatment Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Uterine Fibroid Treatment Revenue, 2025
Table 13. Global Uterine Fibroid Treatment Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Uterine Fibroid Treatment Companies Headquarters
Table 15. Global Uterine Fibroid Treatment Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Uterine Fibroid Treatment Revenue by Type (US$ Million), 2021-2026
Table 19. Global Uterine Fibroid Treatment Revenue by Type (US$ Million), 2027-2032
Table 20. Global Uterine Fibroid Treatment Revenue by Treatment Modality (US$ Million), 2021-2026
Table 21. Global Uterine Fibroid Treatment Revenue by Treatment Modality (US$ Million), 2027-2032
Table 22. Global Uterine Fibroid Treatment Revenue by Technological Approach (US$ Million), 2021-2026
Table 23. Global Uterine Fibroid Treatment Revenue by Technological Approach (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Uterine Fibroid Treatment Revenue by End Use (US$ Million), 2021-2026
Table 26. Global Uterine Fibroid Treatment Revenue by End Use (US$ Million), 2027-2032
Table 27. Uterine Fibroid Treatment High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by End Use
Table 30. North America Uterine Fibroid Treatment Growth Accelerators and Market Barriers
Table 31. North America Uterine Fibroid Treatment Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Uterine Fibroid Treatment Growth Accelerators and Market Barriers
Table 33. Europe Uterine Fibroid Treatment Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Uterine Fibroid Treatment Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Uterine Fibroid Treatment Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Uterine Fibroid Treatment Investment Opportunities and Key Challenges
Table 37. Central and South America Uterine Fibroid Treatment Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Uterine Fibroid Treatment Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Uterine Fibroid Treatment Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Boston Scientific Corporation Information
Table 41. Boston Scientific Description and Major Businesses
Table 42. Boston Scientific Product Features and Attributes
Table 43. Boston Scientific Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Boston Scientific Revenue Proportion by Product in 2025
Table 45. Boston Scientific Revenue Proportion by End Use in 2025
Table 46. Boston Scientific Revenue Proportion by Geographic Area in 2025
Table 47. Boston Scientific Uterine Fibroid Treatment SWOT Analysis
Table 48. Boston Scientific Recent Developments
Table 49. CooperSurgical Corporation Information
Table 50. CooperSurgical Description and Major Businesses
Table 51. CooperSurgical Product Features and Attributes
Table 52. CooperSurgical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. CooperSurgical Revenue Proportion by Product in 2025
Table 54. CooperSurgical Revenue Proportion by End Use in 2025
Table 55. CooperSurgical Revenue Proportion by Geographic Area in 2025
Table 56. CooperSurgical Uterine Fibroid Treatment SWOT Analysis
Table 57. CooperSurgical Recent Developments
Table 58. Karl Storz Corporation Information
Table 59. Karl Storz Description and Major Businesses
Table 60. Karl Storz Product Features and Attributes
Table 61. Karl Storz Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Karl Storz Revenue Proportion by Product in 2025
Table 63. Karl Storz Revenue Proportion by End Use in 2025
Table 64. Karl Storz Revenue Proportion by Geographic Area in 2025
Table 65. Karl Storz Uterine Fibroid Treatment SWOT Analysis
Table 66. Karl Storz Recent Developments
Table 67. Merit Medical Corporation Information
Table 68. Merit Medical Description and Major Businesses
Table 69. Merit Medical Product Features and Attributes
Table 70. Merit Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Merit Medical Revenue Proportion by Product in 2025
Table 72. Merit Medical Revenue Proportion by End Use in 2025
Table 73. Merit Medical Revenue Proportion by Geographic Area in 2025
Table 74. Merit Medical Uterine Fibroid Treatment SWOT Analysis
Table 75. Merit Medical Recent Developments
Table 76. Olympus Corporation Information
Table 77. Olympus Description and Major Businesses
Table 78. Olympus Product Features and Attributes
Table 79. Olympus Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Olympus Revenue Proportion by Product in 2025
Table 81. Olympus Revenue Proportion by End Use in 2025
Table 82. Olympus Revenue Proportion by Geographic Area in 2025
Table 83. Olympus Uterine Fibroid Treatment SWOT Analysis
Table 84. Olympus Recent Developments
Table 85. Richard Wolf Corporation Information
Table 86. Richard Wolf Description and Major Businesses
Table 87. Richard Wolf Product Features and Attributes
Table 88. Richard Wolf Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Richard Wolf Recent Developments
Table 90. Chongqing Haifu Corporation Information
Table 91. Chongqing Haifu Description and Major Businesses
Table 92. Chongqing Haifu Product Features and Attributes
Table 93. Chongqing Haifu Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Chongqing Haifu Recent Developments
Table 95. Haiying Medical Corporation Information
Table 96. Haiying Medical Description and Major Businesses
Table 97. Haiying Medical Product Features and Attributes
Table 98. Haiying Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Haiying Medical Recent Developments
Table 100. Puluo Medical Corporation Information
Table 101. Puluo Medical Description and Major Businesses
Table 102. Puluo Medical Product Features and Attributes
Table 103. Puluo Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Puluo Medical Recent Developments
Table 105. Shanghai Aishen Technology Corporation Information
Table 106. Shanghai Aishen Technology Description and Major Businesses
Table 107. Shanghai Aishen Technology Product Features and Attributes
Table 108. Shanghai Aishen Technology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Shanghai Aishen Technology Recent Developments
Table 110. Hologic Corporation Information
Table 111. Hologic Description and Major Businesses
Table 112. Hologic Product Features and Attributes
Table 113. Hologic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Hologic Recent Developments
Table 115. Medtronic Corporation Information
Table 116. Medtronic Description and Major Businesses
Table 117. Medtronic Product Features and Attributes
Table 118. Medtronic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Medtronic Recent Developments
Table 120. Terumo Corporation Information
Table 121. Terumo Description and Major Businesses
Table 122. Terumo Product Features and Attributes
Table 123. Terumo Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Terumo Recent Developments
Table 125. INSIGHTEC Corporation Information
Table 126. INSIGHTEC Description and Major Businesses
Table 127. INSIGHTEC Product Features and Attributes
Table 128. INSIGHTEC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. INSIGHTEC Recent Developments
Table 130. Profound Medical Corporation Information
Table 131. Profound Medical Description and Major Businesses
Table 132. Profound Medical Product Features and Attributes
Table 133. Profound Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Profound Medical Recent Developments
Table 135. Technologies, Platforms and Infrastructure
Table 136. Distributors List
Table 137. Market Trends and Market Evolution
Table 138. Market Drivers and Opportunities
Table 139. Market Challenges, Risks, and Restraints
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Uterine Fibroid Treatment Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Operation Treatment Product Picture
Figure 3. Ablation Technique Product Picture
Figure 4. Embolization Technique Product Picture
Figure 5. Global Uterine Fibroid Treatment Market Size Growth Rate by Treatment Modality, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Minimally Invasive Procedures Product Picture
Figure 7. Surgical Therapy Product Picture
Figure 8. Other Product Picture
Figure 9. Global Uterine Fibroid Treatment Market Size Growth Rate by Technological Approach, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Image-Guided Therapy Product Picture
Figure 11. Robotic-Assisted Surgery Product Picture
Figure 12. Other Product Picture
Figure 13. Global Uterine Fibroid Treatment Market Size Growth Rate by End Use, 2021 vs 2025 vs 2032 (US$ Million)
Figure 14. Transcervical Fibroid Ablation
Figure 15. Laparoscopic Fibroid Ablation
Figure 16. Hysteroscopic Myomectomy
Figure 17. Uterine Fibroid Embolization (UFE/UAE)
Figure 18. Other
Figure 19. Uterine Fibroid Treatment Report Years Considered
Figure 20. Global Uterine Fibroid Treatment Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 22. Global Uterine Fibroid Treatment Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Uterine Fibroid Treatment Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Uterine Fibroid Treatment Revenue-Based Market Share Ranking (2025)
Figure 25. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 26. Operation Treatment Revenue-Based Market Share by Player in 2025
Figure 27. Ablation Technique Revenue-Based Market Share by Player in 2025
Figure 28. Embolization Technique Revenue-Based Market Share by Player in 2025
Figure 29. Global Uterine Fibroid Treatment Revenue-Based Market Share by Type (2021-2032)
Figure 30. Global Uterine Fibroid Treatment Revenue-Based Market Share by Treatment Modality (2021-2032)
Figure 31. Global Uterine Fibroid Treatment Revenue-Based Market Share by Technological Approach (2021-2032)
Figure 32. Global Uterine Fibroid Treatment Revenue-Based Market Share by End Use (2021-2032)
Figure 33. North America Uterine Fibroid Treatment Revenue YoY (US$ Million), 2021-2032
Figure 34. North America Top 5 Players Uterine Fibroid Treatment Revenue (US$ Million) in 2025
Figure 35. North America Uterine Fibroid Treatment Revenue (US$ Million) by End Use (2021-2032)
Figure 36. US Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 37. Canada Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 38. Mexico Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 39. Europe Uterine Fibroid Treatment Revenue YoY (US$ Million), 2021-2032
Figure 40. Europe Top 5 Players Uterine Fibroid Treatment Revenue (US$ Million) in 2025
Figure 41. Europe Uterine Fibroid Treatment Revenue (US$ Million) by End Use (2021-2032)
Figure 42. Germany Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 43. France Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 44. U.K. Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 45. Italy Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 46. Russia Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 47. Asia-Pacific Uterine Fibroid Treatment Revenue YoY (US$ Million), 2021-2032
Figure 48. Asia-Pacific Top 8 Players Uterine Fibroid Treatment Revenue (US$ Million) in 2025
Figure 49. Asia-Pacific Uterine Fibroid Treatment Revenue (US$ Million) by End Use (2021-2032)
Figure 50. Indonesia Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 51. Japan Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 52. South Korea Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 53. Australia Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 54. India Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 55. Indonesia Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 56. Vietnam Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 57. Malaysia Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 58. Philippines Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 59. Singapore Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 60. Central and South America Uterine Fibroid Treatment Revenue YoY (US$ Million), 2021-2032
Figure 61. Central and South America Top 5 Players Uterine Fibroid Treatment Revenue (US$ Million) in 2025
Figure 62. Central and South America Uterine Fibroid Treatment Revenue (US$ Million) by End Use (2021-2032)
Figure 63. Brazil Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 64. Argentina Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 65. Middle East and Africa Uterine Fibroid Treatment Revenue YoY (US$ Million), 2021-2032
Figure 66. Middle East and Africa Top 5 Players Uterine Fibroid Treatment Revenue (US$ Million) in 2025
Figure 67. Middle East and Africa Uterine Fibroid Treatment Revenue (US$ Million) by End Use (2021-2032)
Figure 68. GCC Countries Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 69. Israel Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 70. Egypt Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 71. South Africa Uterine Fibroid Treatment Revenue (US$ Million), 2021-2032
Figure 72. Uterine Fibroid Treatment Value Chain Mapping
Figure 73. Channels of Distribution (Direct Vs Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed